

Attorney Docket No. P30563

Application No. 10/598,275

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ryozo NAGAI et al.

Group Art Unit: Unassigned

Appln. No. : 10/598,275
(U.S. National Stage Entry of PCT/JP05/002986)

Examiner: Unassigned

I.A Filed : February 24, 2005

Confirmation No.: 2170

For : MEDICINE CAPABLE OF INHIBITING ACTIVATION OF
TRANSCRIPTION FACTOR KLF5

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants hereby bring the following information to the attention of the Examiner, which includes information cited and discussed in the specification, the International Search Report, the Written Opinion and the International Preliminary Examination Report issued in connection with counterpart International Application No. PCT/JP05/002986. Copies of the International Search Report (in English and Japanese), the Written Opinion (in Japanese) and the International Preliminary Examination Report (in Japanese) were enclosed with the papers when entering the National Stage on September 1, 2005. The Examiner is invited to review these materials to inspect the relevance indicated during international examination with respect to the documents cited therein.

J. GEORGE et al., "Inhibition of Intimal Thickening in the Injury Model by a Nontoxic Ras Inhibitor", *Arterioscler Thromb Vasc. Biol.* Feb. 2004, Vol. 24, No. 2, pp. 363-368;

JP 56-140949 A, November 4, 1981, accompanied by an English language abstract thereof;

JP 63-32058 B2, June 28, 1982; Applicants note that this document is cited and discussed in the application beginning on page 4 of the specification and is identified on esp@cenet as a family member of JP 56-140949 A;

JP 7-112930 A, May 2, 1995, accompanied by an English language abstract thereof;

U.S. Patent No. 4,917,829 (YAMATSU et al.), April 17, 1990; Applicants note that this document is identified on the International Search Report as a U.S. family member of JP 56-140949 A and JP 7-112930 A;

JP 61-210050 A, September 18, 1986, accompanied by an English language abstract thereof;

EP 0 194 693 A1, September 19, 1986; Applicants note that this document is identified on the International Search Report as an English language family member of JP 61-210050 A;

JP 59-101448 A, June 12, 1984, accompanied by an English language abstract thereof;

EP 0 110 397 A2, June 13, 1984; Applicants note that this document is identified on the International Search Report as an English language family member of JP 59-101448 A;

JP 10-316617 A, December 2, 1998, accompanied by an English language abstract thereof;

JP 4-178348 A, June 25, 1992, accompanied by an English language abstract thereof; and

Y. MUTO et al., "Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma", N. Engl. J. Med., June 13, 1996, Vol. 334, No. 24, pp. 1561-1567.

Applicants further direct the attention of the Examiner to the following documents cited and discussed in the specification of the present application:

N. WATANBE et al., "BTEB2, A Krüppel-Like Transcription Factor, Regulates Expression of the SMemb/Nonmuscle Myosin Heavy Chain B (SMemb/NMHC-B) Gene", Circulation Research, 85, pp.182-191, 1999; Applicants note that this document is cited and discussed in the application beginning on page 1 of the specification;

JP 11-318450 A, November 24, 1999, accompanied by an English language abstract thereof; Applicants note that this document is cited and discussed in the application beginning on page 2 of the specification;

T. SHINDO et al., "Krüppel-Like Zinc-Finger Transcription Factor KLF5/BTEB2 is a Target for Angiotensin II Signaling and an Essential Regulator of Cardiovascular Remodeling", Nature Medicine, Vol. 8, No. 8, pp.856-863, July 8, 2002; Applicants note that this document is cited and discussed in the application beginning on page 2 of the specification; and

J. DAVIS et al., "Cartenoids and Related Compounds. Part XV. The Structure and Synthesis of Phytoene, Phytofluene, ζ -Carotene, and Neurosporene", J. Chem. Soc., 1966, pp.2154-2165; Applicants note that this document is cited and discussed in the application beginning on page 4 of the specification.

Furthermore, Applicants direct the attention of the Examiner to the following Commonly Assigned/Co-pending U.S. Patent Applications:

U.S. Patent Application 10/511,274 (NAGAI et al.), published as U.S. 2005/0234130 A1 on October 20, 2005 and entitled, "Medicament for Therapeutic Treatment of Vascular Disease"; Applicants note that this document is the National Stage of PCT/JP03/05084, which published as WO 2003/089005 on October 30, 2005;

U.S. Patent Application 10/565,997 (NAGAI et al.), filed January 27, 2006 and entitled, "RNA Capable of Suppressing Expression of KLF5 Gene"; Applicants note that this document is the National Stage of PCT/JP04/11223, which published as WO 2005/010185 on February 3, 2005; and

U.S. Patent Application 11/366,454 (NAGAI et al.), published as U.S. 2007/0049579 A1 on March 1, 2007 and entitled, "Medicament Having Neovascularization Promoting Action".

Copies of the above-listed documents (with the exception of U.S. patents and U.S. patent applications) and the International Search Report (in English) for International Application PCT/JP05/002986 are enclosed together with a completed copy of the PTO-1449 Form listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Further to 37 C.F.R. §1.98 (a)(2)(ii) and to the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. §1.98 (a)(2)(iii) if a U.S. patent application was filed after June 30, 2003, copies of the U.S. patents and patent applications are not enclosed herewith. However, if a copy is needed, the Examiner is respectfully requested to contact the undersigned.


Attorney Docket No. P30563

Application No. 10/598,275

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is believed necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Royozo NAGAI et al.


Bruce H. Bernstein
Reg. No. 29,027 42,920

March 28, 2007
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

FORM PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
P30653Application No.
10/598,275INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)Applicant
Ryozo NAGAI et al.Filing Date
February 24, 2005Group
Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4 9 1 7 8 2 9	04/17/90	YAMATSU et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	56	- 1 4 0 9 4 9	11/04/81	JAPAN				
	63	- 3 2 0 5 8	06/28/82	JAPAN				
	7	- 1 1 2 9 3 0	05/02/95	JAPAN				
	61	- 2 1 0 0 5 0	09/18/86	JAPAN				
		0 1 9 4 6 9 3	09/19/86	E.P.O				
	59	- 1 0 1 4 4 8	06/12/84	JAPAN				
		0 1 1 0 3 9 7	06/13/84	E.P.O				
	10	- 3 1 6 6 1 7	12/02/98	JAPAN				
	4	- 1 7 8 3 4 8	06/25/92	JAPAN				
	11	- 3 1 8 4 5 0	11/24/99	JAPAN				
	2003	/ 0 8 9 0 0 5	10/30/05	W.I.P.O				
	2005	/ 0 1 0 1 8 5	02/03/05	W.I.P.O				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	J. GEORGE et al., "Inhibition of Intimal Thickening in the Injury Model by a Nontoxic Ras Inhibitor", Arterioscler Thromb Vasc. Biol. Feb. 2004, Vol. 24, No. 2, pp. 363-368.
	2	Y. MUTO et al., "Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma", N. Engl. J. Med., June 13, 1996, Vol. 334, No. 24, pp. 1561-1567.
	3	N. WATANBE et al., "BTEB2, A Krüppel-Like Transcription Factor, Regulates Expression of the SMemb/Nonmuscle Myosin Heavy Chain B (SMemb/NMHC-B) Gene", Circulation Research, 85, pp.182-191, 1999.
	4	T. SHINDO et al., "Krüppel-Like Zinc-Finger Transcription Factor KLF5/BTEB2 is a Target for Angiotensin II Signaling and an Essential Regulator of Cardiovascular Remodeling", Nature Medicine, Vol. 8, No. 8, pp.856-863, July 8, 2002.
	5	J. DAVIS et al., "Cartenoids and Related Compounds. Part XV. The Structure and Synthesis of Phytoene, Phytofluene, ζ -Carotene, and Neurosporene", J. Chem. Soc., 1966, pp.2154-2165.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce
Patent and Trademark Office

Application No.
10/598,275

Applicant
Ryozo NAGAI et al.

Filing Date
February 24, 2005

Group
Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	6	English language Abstract of JP 56-140949.
	7	English language Abstract of JP 7-112930.
	8	English language Abstract of JP 61-210050.
	9	English language Abstract of JP 10-316617.
	10	English language Abstract of JP 4-178348.
	11	English language Abstract of JP 11-318450.
	12	U.S. Patent Application 10/511,274 (NAGAI et al.), entitled, "Medicament for Therapeutic Treatment of Vascular Disease"
	13	U.S. Patent Application 10/565,997 (NAGAI et al.), entitled, "RNA Capable of Suppressing Expression of KLF5 Gene"
	14	U.S. Patent Application 11/366,454 (NAGAI et al.), entitled, "Medicament Having Neovascularization Promoting Action".

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.